Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers
This invention concerns spiro azepane-ox-azolidinones as voltage gated Kv1.3 potassium channel blockers, pharmaceutical compositions containing these compounds, methods for preparing the compounds, methods for preparing novel intermediates useful for their synthesis, and methods for preparing compositions. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in the treatment of diabetes, psoriasis, obesity, transplant rejection and inflammatory neuropathies, including T-cell mediated autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. The compounds have formula (1): wherein R 1 , R 2 , (R 3 ) n , and (R 4 ) m have the meanings given in the specification.
1. A compound of formula (1):
wherein:
each of R 1 and R 2 is chosen from hydrogen, deuterium, fluorine, CF 3 , and alkyl(C 1-3 ), which may be unsubstituted or substituted with one or more fluorine atoms,
n is an integer chosen from 0, 1, and 2,
R 3 is chosen from halogen, alkyl(C 1-3 ), CF 3 , CN, NH 2 , NHAc, OH, OCH 3 , and OCF 3 ,
m is an integer chosen from 0, 1, 2, and 3, and
R 4 is chosen from halogen, alkyl(C 1-3 ), CF 3 , CN, NH 2 , NHAc, OH, OCH 3 , and OCF 3 , or
(R 4 ) m and the phenyl ring to which it is attached form a naphthyl group,
or a tautomer, a stereoisomer, or a pharmacologically acceptable salt of any of the foregoing.
2. A compound according to claim 1 , wherein each of R 1 and R 2 are hydrogen or methyl, n is 0 or 1, R 3 is halogen, m is 1 or 2, and R 4 is chosen from halogen, CF 3 , CN, OCH 3 , and OCF 3 , or (R 4 ) m and the phenyl ring to which it is attached form a naphthyl group.
3. A compound according to claim 1 , wherein the compound is chosen from:
(5S)-8-[3,5-bis(trifluoromethyl)benzoyl]-3-[(1S)-1-phenylethyl]-1-oxa-3,8-diazaspiro[4.6]-undecan-2-one,
(5R)-8-[3,5-bis(trifluoromethyl)benzoyl]-3-[(1S)-1-phenylethyl]-1-oxa-3,8-diazaspiro[4.6]-undecan-2-one,
(5R)-8-[3,5-bis(trifluoromethyl)benzoyl]-3-[(1R)-1-phenylethyl]-1-oxa-3,8-diazaspiro[4.6]-undecan-2-one,
(5S)-8-[3,5-bis(trifluoromethyl)benzoyl]-3-[(1R)-1-phenylethyl]-1-oxa-3,8-diazaspiro[4.6]-undecan-2-one,
(5S)-8-[3-cyanobenzoyl]-3-[(1S)-1-phenylethyl]-1-oxa-3,8-diazaspiro[4.6]undecan-2-one,
(5R)-8-[3-cyanobenzoyl]-3-[(1S)-1-phenylethyl]-oxa-3,8-diazaspiro[4.6]undecan-2-one,
(5R)-8-[3-cyanobenzoyl]-3-[(1R)-1-phenylethyl]-1-oxa-3,8-diazaspiro[4.6]undecan-2-one, and
(5S)-8-[3-cyanobenzoyl]-3-[(1R)-1-phenylethyl]-1-oxa-3,8-diazaspiro[4.6]undecan-2-one.
4. A compound according to claim 1 , wherein said compound is an optically active enantiomer or diastereoisomer.
5. A compound according to claim 1 , wherein the carbon atom attached to the nitrogen atom of the oxazolinone ring is the (R) or (S) enantiomer.
6. A compound according to claim 1 , wherein the central quaternary spiro-carbon atom is the (R) or (S) enantiomer.
7. A compound of formula (v):
wherein
each of R 1 and R 2 is chosen from hydrogen, deuterium, fluorine, CF 3 , and alkyl(C 1-3 ), which may be unsubstituted or substituted with one or more fluorine atoms,
n is an integer chosen from 0, 1, and 2, and
R 3 is chosen from halogen, alkyl(C 1-3 ), CF 3 , CN, NH 2 , NHAc, OH, OCH 3 , and OCF 3 .
8. A compound of formula (vi):
wherein
each of R 1 and R 2 is chosen from hydrogen, deuterium, fluorine, CF 3 , and alkyl(C 1-3 ), which may be unsubstituted or substituted with one or more fluorine atoms,
n is an integer chosen from 0, 1, and 2, and
R 3 is chosen from halogen, alkyl(C 1-3 ), CF 3 , CN, NH 2 , NHAc, OH, OCH 3 , and OCF 3 .
9. A compound of formula (vii):
wherein
each of R 1 and R 2 is chosen from hydrogen, deuterium, fluorine, CF 3 , and alkyl(C 1-3 ), which may be unsubstituted or substituted with one or more fluorine atoms,
n is an integer chosen from 0, 1, and 2, and
R 3 is chosen from halogen, alkyl(C 1-3 ), CF 3 , CN, NH 2 , NHAc, OH, OCH 3 , and OCF 3 ,
with the proviso that the compound of formula (vii) is not 3-[(S)-1-phenyl-ethyl]-1-oxa-3,8-diazaspiro[4.6]undecan-2-one.
10. A compound according to claim 9 , wherein the compound is:
11. A method for preparing a compound according to claim 1 , the method comprising:
(i) protecting the amino group of hexahydro(1H)-azepin-4-one with a protecting group, yielding a ketone of formula 2:
(ii) epoxidizing the ketone of formula 2 to a spiro-epoxide of formula 3:
(iii) aminolysing of the spiro-expoxide of formula 3, with an amine 4 of formula RNH 2 , wherein R represents the moiety:
and wherein each of R 1 and R 2 is chosen from hydrogen, deuterium, fluorine, CF 3 , and alkyl(C 1-3 ), which may be unsubstituted or substituted with one or more fluorine atoms; n is an integer chosen from 0, 1, and 2; R 3 is chosen from halogen, alkyl(C 1-3 ), CF 3 , CN, NH 2 , NHAc, OH, OCH 3 , and OCF 3 ; m is an integer chosen from 0, 1, 2, and 3, to yield an aminoalcohol of formula 5:
(iv) ring closing of the aminoalcohol of formula 5, in the presence of a carbonylating agent, catalyzed by DMAP, to yield the spiro-oxazolidinone derivative of formula 6, and
(v) deprotecting the spiro-oxazolidinone of formula 6, yielding a compound of formula 7.
12. The method according to claim 11 , wherein said protecting group is chosen from a benzyloxycarbonyl (Cbz) and a tert-butoxycarbonyl (t-Boc) group.
13. A method for treating at least one condition chosen from diabetes, psoriasis, obesity, transplant rejection, and inflammatory neuropathies, -cell mediated autoimmune diseases, rheumatoid arthritis, and multiple sclerosis, the method comprising administering a compound of formula (1) to a patient in need of such treatment, wherein the compound of formula (1) is:
wherein:
each of R 1 and R 2 is chosen from hydrogen, deuterium, fluorine, CF 3 , and alkyl(C 1-3 ), which may be unsubstituted or substituted with one or more fluorine atoms,
n is an integer chosen from 0, 1, and 2,
R 3 is chosen from halogen, alkyl(C 1-3 ), CF 3 , CN, NH 2 , NHAc, OH, OCH 3 , and OCF 3 ,
m is an integer chosen from 0, 1, 2, and 3, and
R 4 is chosen from halogen, alkyl(C 1-3 ), CF 3 , CN, NH 2 , NHAc, OH, OCH 3 , and OCF 3 , or
(R 4 ) m and the phenyl ring to which it is attached form a naphthyl group,
or a tautomer, a stereoisomer, or a pharmacologically acceptable salt of any of the foregoing.
14. A pharmaceutical composition comprising at least one pharmaceutically acceptable carrier, or at least one pharmaceutically acceptable auxiliary substance, or a combination of two or more thereof; and a pharmacologically active amount of at least one compound of formula (1):
or a pharmacologically acceptable salt thereof, wherein:
each of R 1 and R 2 are chosen from hydrogen, deuterium, fluorine, CF 3 , and alkyl(C 1-3 ), unsubstituted or substituted with one or more fluorine atoms,
n is an integer chosen from 0, 1, and 2, R 3 is chosen from halogen, alkyl(C 1-3 ), CF 3 , CN, NH 2 , NHAc, OH, OCH 3 , and OCF 3 ,
m is an integer chosen from 0, 1, 2, and 3, and
R 4 is chosen from halogen, alkyl(C 1-3 ), CF 3 , CN, NH 2 , NHAc, OH, OCH 3 , and OCF 3 , or
(R 4 ) m and the phenyl ring to which it is attached form a naphthyl group.